Fortvita Advances Zybrivo for First-Line Lung Cancer Treatment
Palo Alto, California, USA, November 16, 2026 Fortvita Biologics has received its first positive recommendation from the European Medicines...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Palo Alto, California, USA, November 16, 2026 Fortvita Biologics has received its first positive recommendation from the European Medicines...
Palo Alto, California, USA, and Suzhou, China, November 15, 2026 Innovent Biologics has announced that its immunotherapy Zybrivo® (sintilimab)...
Berlin, Germany, and Beijing, China, November 4, 2026 Bayer has announced that China’s National Medical Products Administration (NMPA) has...
ROCKVILLE, Maryland, October 29, 2026 OncoC4, Inc., a late clinical-stage biopharmaceutical company developing innovative medicines for cancer and immunological...
Nantes, France — October 29, 2026 OSE Immunotherapeutics SA reported final positive results from its Combi-TED Phase 2 randomized...
Chengdu, China, October 27, 2026 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced that China’s National Medical Products Administration (NMPA)...
Basel, Switzerland — October 28, 2026 Roche, a global healthcare company operating across pharmaceuticals and diagnostics, announced the global...
HONG KONG, SHANGHAI and FLORHAM PARK, N.J. — September 29, 2026 HUTCHMED (China) Limited announced that AstraZeneca has submitted...
OSAKA, Japan and CAMBRIDGE, Mass. — September 22, 2026 Takeda announced that new data from its oncology pipeline and...
Houston, Texas, U.S., September 22, 2026 Iterion Therapeutics has announced promising results from a Phase 1b clinical study evaluating...
